Published Studies Related to Rhogam Ultra-Filtered Plus (Rho(d) Immune Globulin Human)
Well-designed clinical trials possibly related to Rhogam Ultra-Filtered Plus (Rho(d) Immune Globulin Human)
Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia. [2011.05]
Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura. [2008.12]
Women's attitude towards prenatal screening for red blood cell antibodies, other than RhD. [2008.11.11]
A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children. [2008.08]
Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin. [2008.07]
The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies. [2007.10]
Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. [2007.05]
THROMBOCYTOPENIA ASSOCIATED WITH DENGUE HEMORRHAGIC FEVER RESPONDS TO INTRAVENOUS ADMINISTRATION OF ANTI-D (RH0-D) IMMUNE GLOBULIN. [2007.04]
Other possibly related research studies
Receipt of older RBCs does not predispose D-negative recipients to anti-D alloimmunization. [2010.09]
Isolated early onset anemia after rh isoimmunization: a unique presentation in 3 neonates. [2010.08]
Evaluation of the effects of and earliest response rate to anti-D treatment in children with chronic idiopathic thrombocytopenic purpura: a pilot study. [2010.03]
Prevention of RhD alloimmunization in RhD negative women. [2010.03]
Predictors of chronic idiopathic thrombocytopenic purpura. [2010.07.01]
[Follow-up of pregnancies with red-cell allo-immunisation: State-of-the art] [2010.03]
Incidence and risk factors for community-acquired hepatitis C infection from birth to 5 years of age in rural Egyptian children. [2010.05]
Predicting response to splenectomy in children with immune thrombocytopenic purpura. [2010.01]
Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura. [2010.04]
[EMABling antibodies: from feto-maternal allo-immunisation prophylaxis to chronic lymphocytic leukaemia therapy] [2009.12]
Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. [2010]
Prevention of Rh sensitization in the context of trauma: two case reports. [2010]
Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. [2009]
Molecular biology of the Rh system: clinical considerations for transfusion in sickle cell disease. [2009]
Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. [2009.12]
A curious case of anti-D antibody titer. [2009.11]
D+ platelet transfusions in D- patients: cause for concern? [2009]
Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia. [2009.11]
Subcutaneous anti-D globulin application is a safe treatment option of immune thrombocytopenia in children. [2010.04]
Immune thrombocytopenia in children with reference to low-income countries. [2009.05]
Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models? [2009.11]
Primary anti-D immunization by DEL red blood cells. [2009.08]
Exchange transfusion of least incompatible blood for severe hemolytic disease of the newborn due to anti-Rh17. [2010.02]
Subcutaneous anti-D treatment of idiopathic thrombocytopenic purpura in children. [2009.12.15]
Rh D foeto-maternal alloimmunization prophylaxis with anti-D immunoglobulins reviewed in the era of foetal RHD genotyping. [2009.05]
Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. [2009.08]
Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products. [2009.10]
Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. [2009.09]
Severe hemolytic anemia post-renal transplantation produced by donor anti-D passenger lymphocytes: case report and literature review. [2009.04]
Passenger lymphocyte syndrome with or without immune hemolytic anemia in all Rh-positive recipients of lungs from rhesus alloimmunized donors: three new cases and a review of the literature. [2009.04]
Inaccurate doses of R immune globulin after rh-incompatible fetomaternal hemorrhage: survey of laboratory practice. [2009.03]
Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model. [2009.06]
Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. [2009.02]
Reduction of disulfide bonds within anti-D results in enhanced Fcgamma receptor blockade. [2009.05]
Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. [2009.01.15]
Immunologic basis and immunoprophylaxis of RhD induced hemolytic disease of the newborn (HDN). [2008.12]
Plasmapheresis and intravenous immune globulin for the treatment of D alloimmunization in pregnancy. [2008]
Rapid encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura. [2008]
Implementation of NICE recommendation for a policy of routine antenatal anti-D prophylaxis: a survey of UK maternity units. [2008.10]
Immune regulation by B cells and antibodies a view towards the clinic. [2008]
Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn. [2008.10]
Immune thrombocytopenic purpura. [2008.07]
Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden. [2008]
The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. [2008.11]
Control of massive bleeding in dengue hemorrhagic fever with severe thrombocytopenia by use of intravenous anti-D globulin. [2008.12]
Management of rhesus alloimmunization in pregnancy. [2008.07]
Refractory immune thrombocytopenic purpura: current strategies for investigation and management. [2008.10]
Prevention of D sensitization after mismatched transfusion of blood components: toward optimal use of RhIG. [2008.09]
Maternal Rh D status, anti-D immune globulin exposure during pregnancy, and risk of autism spectrum disorders. [2008.09]
A combined flow cytometry-based method for fetomaternal hemorrhage and maternal D. [2008.09]
One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. [2008.08]
Massive fetomaternal hemorrhage: clearance of fetal red blood cells after intravenous anti-D prophylaxis monitored by flow cytometry. [2008.08]
Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens? [2008.05]
Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin. [2007.12]
Prospective evaluation of a transfusion policy of D+ red blood cells into D- patients. [2008.07]
Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment. [2008.04]
A single-institution, 20-year prospective experience with an affordable Fc-receptor blockade method to treat patients with chronic, refractory autoimmune thrombocytopenic purpura. [2007.11]
Management of suspected ectopic pregnancy: An audit from East Kent NHS Hospital Trust. [2008.02]
First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. [2008.02]
Transfusion-related acute lung injury following intravenous anti-D administration in an adolescent. [2008.08]
An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients. [2008.04]
A confusion in antibody identification: anti-D production after anti-hrB. [2007]
Management of pregnancy complicated by anti-hrB/anti-HrB. [2007]
A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. [2008.04]
Immunoglobulin G-mediated regulation of the murine immune response to transfused red blood cells occurs in the absence of active immune suppression: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the fetus and newborn? [2008.05]
Clinical validation of routine antenatal anti-D prophylaxis questions the modelling predictions adopted by NICE for Rhesus D sensitisation rates: results of a longitudinal study. [2008.07]
Current options for the treatment of idiopathic thrombocytopenic purpura. [2007.10]
Utilization of anti-RhD in the emergency department after blunt trauma. [2008.02]
Cerebral venous thrombosis after immune thrombocytopenic purpura and anti-D immune globulin therapy. [2008.03]
A review of Thimerosal (Merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness. [2007.12]
Immune thrombocytopenic purpura in adults. [2007.09]
Update on the management of immune thrombocytopenic purpura in children. [2007.09]
New therapies for immune thrombocytopenic purpura. [2007.09]
Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen. [2007.10]
IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn? [2007.10]
Anti-D immunoglobulin-induced prolonged intravascular hemolysis and neutropenia. [2007.09]
In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn. [2008.01]
Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. [2007.08]
A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders. [2007.05]
Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura. [2007.08]
Comparison of two techniques for the evaluation of fetomaternal hemorrhage in RhD-negative women: gel agglutination and haemoglobin F determination by flow cytometry. [2007]
[Screening analysis of irregular antibodies from random donor population in Shaoguan area] [2007.06]
Atopic sensitization and the international variation of asthma symptom prevalence in children. [2007.09.15]
Lack of association between Rh status, Rh immune globulin in pregnancy and autism. [2007.07.01]
A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. [2007.05.15]
Intravenous anti-D immunoglobulin in the treatment of resistant immune thrombocytopenic purpura in pregnancy. [2007.04]
A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). [2007.02]
Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care. [2011.07]
Management of immune thrombocytopenic purpura in children: potential role of novel agents. [2011.08.01]
[The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn]. [2011.03]
[Calculation of feto-maternal haemorrhage volume using various morphological parameters and various formulas]. [2011.03]
[Management of feto-maternal red cell allo-immunizations]. [2011.04]
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. [2011.05.26]
|
